Lercanidipine hydrochloride

CAS No. 132866-11-6

Lercanidipine hydrochloride( Lercanidipine hydrochloride | Renovia | Vasodip | R 75 )

Catalog No. M17950 CAS No. 132866-11-6

Lercanidipine is a calcium channel blocker of the dihydropyridine class.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 46 In Stock
50MG 27 In Stock
100MG 45 In Stock
200MG Get Quote In Stock
500MG 164 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lercanidipine hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Lercanidipine is a calcium channel blocker of the dihydropyridine class.
  • Description
    Lercanidipine hydrochloride is a calcium channel blocker used in the treatment of hypertension.
  • In Vitro
    Western Blot Analysis Cell Line:LPS/IFN-γ-induced VSMC Concentration:1 and 10 μM Incubation Time:24 h Result:Down-regulated LPS/IFN-γ-induced iNOS, MMP-2/-9, NF-kB expression and IkB-a phosphorylation. Decreased cytosolic HMGB1 fraction and extracellular HMGB1 release while increasing nuclear HMGB1 fraction.
  • In Vivo
    Animal Model:Albino male Wistar rats, middle cerebral artery occlusion (MCAo) modelDosage:1, 0.5 and 0.25 mg/kg Administration:Intraperitoneal injection (i.p.), acute administrationResult:Showed neuroprotective effect in focal cerebral ischemic-reperfusion injury model, most effective dose was found to be at 0.5 mg/kg. Significantly attenuated percentage infarct volume, significantly improved the apparent diffusion coefficient. Declined MMP-9 activity significantly in all Lercanidipine treated groups till 240 min post-reperfusion, while MMP-2 activity was inhibited only till 120 min post-reperfusion. Decreased caspase-3 activity significantly in Lercanidipine 15 and 120 min post-reperfusion groups only. Exhibited significant reduction in caspase-9 activity in all groups except at 240 min post-reperfusion group.Animal Model:Male SHRs Dosage:1.92, 0.96, 0.48, 0.24 and 0.12 mg/kg Administration:Oral gavage (p.o.) for once Result:Increased the AOC values of mean arterial pressure in a dose-dependent manner (285.4 mmHg×hour for 1.92 mg) as well as decreased BP.
  • Synonyms
    Lercanidipine hydrochloride | Renovia | Vasodip | R 75
  • Pathway
    Endocrinology/Hormones
  • Target
    AChR
  • Recptor
    Calcium Channel
  • Research Area
    Cardiovascular Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    132866-11-6
  • Formula Weight
    648.19
  • Molecular Formula
    C36H41N3O6·HCl
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 50 mg/mL 77.14 mM; H2O : < 0.1 mg/mL
  • SMILES
    CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1)c1cc(ccc1)[N+](=O)[O-])C(=O)OC.Cl
  • Chemical Name
    3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Gigant B, et al. Nature, 2005, 435(7041), 519-522.
molnova catalog
related products
  • Solifenacin succinat...

    Solifenacin Succinate(YM905; Vesicare) is a muscarinic receptor antagonist.

  • Benzenesulfonamide

    Benzenesulfonamide ia an inhibitor of carbonic anhydrases.

  • Aclidinium bromide

    Aclidinium Bromide inhibits human muscarinic AChR M1, M2, M3, M4 and M5 with Ki of 0.1 nM, 0.14 nM, 0.14 nM, 0.21 nM and 0.16 nM, respectively.